Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo

Biochemical and Biophysical Research Communications

Volumn 345, Issue 3, 2006, Pages 1207-1214

  Perryman, L A ^a,b   Blair, J M ^a,b   Kingsley, E A ^a,b   Szymanska, B ^a,b   Ow, K T ^a,b   Wen, V W ^c   MacKenzie, K L ^c   Vermeulen, P B ^d   Jackson, P ^a,b   Russell, P J ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^d SINT AUGUSTINUS HOSPITAL   (Belgium)

Author keywords

Angiogenesis; Apoptosis; Endostatin; Hypoxia; p53; Proliferation; Prostate cancer; VEGF; Xenografts

Indexed keywords

ENDOSTATIN; GAMMA INTERFERON; MUTANT PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER INHIBITION; CARCINOGENESIS; CELL HYPOXIA; CELL INTERACTION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR NECROSIS; UMBILICAL VEIN;

ANOXIA; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; ENDOTHELIUM, VASCULAR; GENES, P53; HUMANS; MALE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UMBILICAL VEINS;

EID: 33646854692     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.05.020     Document Type: Article

References (38)

1. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 8 (2002) 594-604
2. Fridman J.S., and Lowe S.W. Control of apoptosis by p53. Oncogene 22 (2003) 9030-9040
3. Heidenberg H.B., Bauer J.J., McLeod D.G., Moul J.W., and Srivastava S. The role of the p53 tumour suppressor gene in prostate cancer: a possible biomarker. Urology 48 (1996) 971-979
4. Downing S.R., Russell P.J., and Jackson P. Alterations of p53 are common in early stage prostate cancer. Can. J. Urol. 10 (2003) 1924-1933
5. Quinn D.I., Henshall S.M., Head D.R., Golovsky D., Wilson J.D., Brenner P.C., Turner J.J., Delprado W., Finlayson J.F., Stricker P.D., Grygiel J.J., and Sutherland R.L. Prognostic significance of p53 nuclear accumulation in localised prostate cancer treated with radical prostatectomy. Cancer Res. 60 (2000) 1585-1594
6. Rinker-Schaeffer C.W., Partin A.W., Isaacs W.B., Coffey D.S., and Isaacs J.T. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. Prostate 25 (1994) 249-265
7. Bostwick D.G., Pacelli A., and Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate 29 (1996) 117-134
8. Kauffman E.C., Robinson V.L., Stadler W.M., Sokoloff M.H., and Rinker-Schaeffer C.W. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site. J. Urol. 169 (2003) 1122-1133
9. Chambers A.F., Groom A.C., and MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat. Rev. Cancer 2 (2003) 563-572
10. Stacker S.A., Baldwin M.E., and Achen M.G. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16 (2002) 922-934
11. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
12. Yu E.Y., Yu E., Meyer G.E., and Brawer M.K. The relation of p53 protein nuclear accumulation and angiogenesis in human prostatic cancer. Prostate Cancer Prostatic Dis. 1 (1997) 39-44
13. Kieser A., Weich H.A., Brandner G., Marme D., and Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9 (1994) 963-969
14. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin 1. Science 265 (1994) 1582-1584
15. Park J.E., Keller G.A., and Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extra cellular matrix-bound VEGF. Mol. Biol. Cell 12 (1993) 1317-1326
16. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., and Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271 (1996) 7788-7795
17. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J. Natl. Cancer Inst. 82 (1990) 4-7
18. Mukhopadhyay D., and Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin. Cancer Biol. 14 (2004) 123-130
19. Downing S.R., Bumak C., Nixdorf S., Ow K., Russell P.J., and Jackson P. Mutant p53 in prostate cancer cells is associated with elevated levels of prostate-specific antigen and increased metastasis. Mol. Carcinogen. 38 (2003) 130-140
20. Thalmann G.N., Sikes R.A., Chang S.M., Johnston D.A., von Eschenbach A.C., and Chung L.W.K. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer. J. Natl. Cancer Inst. 88 (1996) 794-801
21. Jackson P., Grimm M.O., Kingsley E.A., Brosius U., Antalis T., Yardley G., and Russell P.J. Relationship between expression of KAI1 metastasis suppressor gene mRNA and p53 in bladder and prostate cancer cell lines. Urol. Oncol. 7 (2002) 99-104
22. MacKenzie K.L., Franco S., Naiyer A.J., May C., Sadelain M., Rafii S., and Moore M.A. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen, and oncogenic N-ras. Oncogene 21 (2002) 4200-4211
23. Russell P.J., Raghavan D., Gregory P., Philips J., Wills E.J., Jelbart M., Wass J., Zbroja R.A., and Vincent P.C. Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Res. 46 (1986) 2035-2040
24. Vermeulen P.B., Gasparini G., Fox S.B., Colpaert C., Marson L.P., Gion M., Belien J.A., de Waal R.M., Van Mark E., Magnani E., Weidner N., Harris A.L., and Dirix L.Y. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 38 (2002) 1564-1579
25. Weidner N., Carroll P.R., Flax J., Blumenfeld W., and Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Pathol. 143 (1993) 401-409
26. Jain R.K. Normalising tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7 (2001) 987-989
27. Bergers G., and Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3 (2003) 401-410
28. Hanahan D., and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 (1996) 353-364
29. Strohmeyer D., Rossing C., Bauerfeind A., Kaufmann O., Schlechte H., Bartsch G., and Loening S. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 45 (2000) 216-224
30. Gong W., Jiang Y., Wang L., Wei D., Yao J., Huang S., Fang S., and Xie K. Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin. Cancer Res. 11 (2005) 5778-5783
31. Tsutsui S., Yasuda K., Suzuki K., Tahara K., Higashi H., and Era S. Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol. Rep. 14 (2005) 425-431
32. Raspollini M.R., Castiglione F., Garbini F., Villanucci A., Amunni G., Baroni G., Boddi V., and Taddei G.L. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int. J. Surg. Pathol. 13 (2005) 135-142
33. Lee J.S., Kim H.S., Park J.T., Lee M.C., and Park C.S. Expression of vascular endothelial growth factor in the progression of cervical neoplasia and its relation to angiogenesis and p53 status. Anal. Quant. Cytol. Histol. 25 (2003) 303-311
34. Yao D.F., Wu X.H., Zhu Y., Shi G.S., Dong Z.Z., Yao D.B., Wu W., Qiu L.W., and Ming X.Y. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat. Dis. Int. 4 (2005) 220-226
35. Zhang J., Peng B., and Chen X. Expressions of nuclear factor kappa B, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin. Cancer Res. 11 (2005) 7334-7343
36. Zyzas P.A., Stefanou D., Bastistatou A., and Agnantis N.J. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 131 (2005) 624-630
37. Couvelard A., O'Toole D., Turley H., Leek R., Sayvenot A., Degott C., Ruszniewski P., Belghiti J., Harris A.L., Gatter K., and Pezzaella F. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br. J. Cancer 92 (2005) 94-101
38. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., and Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14 (2000) 34-44